Emcure Pharma shares rise 2% on deal to distribute Sanofi India's oral anti-diabetic products- Grow Mudra

Emcure Pharma shares rise 2% on deal to distribute Sanofi India's oral anti-diabetic products

17 Jul , 2025 By : Debdeep Gupta

Shares of Emcure Pharmaceuticals and Sanofi India rose 2 percent each after the two teamed up deal to widen the reach of Sanofi’s popular oral anti-diabetic (OAD) brands across the country. The partnership, announced on July 16, aims to strengthen access to diabetes care at a time when India faces a growing public health challenge.

Under the agreement, Emcure will take over the distribution and promotional responsibilities for Sanofi’s key OAD products—such as Amaryl and Cetapin—while Sanofi will continue to own and manufacture the drugs at its domestic and international sites. The collaboration is already in effect.

With this move, both companies are looking to combine strengths—Sanofi’s established brands and Emcure’s deep-rooted reach across Indian markets—to serve the more than 100 million Indians living with type 2 diabetes.

Importantly, there will be no transfer of employees from Sanofi to Emcure as part of the arrangement.

“Over 60 percent of Indians with type 2 diabetes have uncontrolled sugar levels. Through this partnership, we hope to expand the impact of our leading OAD therapies,” said Eric Mansion, General Manager – Pharma, Southeast Asia and India at Sanofi.

Emcure MD and CEO Satish Mehta noted that the alliance complements the company’s current diabetes portfolio and marks another step towards improving access to affordable and high-quality treatment.

Emcure Pharmaceuticals posted a strong performance for the March quarter of FY25, with consolidated net profit surging 64.4 percent year-on-year to Rs 189 crore, compared to Rs 115 crore in the same quarter last year. The company's revenue also posted a strong growth of 19.5 percent YoY, climbing to Rs 2,116 crore, compared to Rs 1,771.3 crore in Q4FY24, reflecting sustained demand across key markets.

At about 9:20 am, shares of the Emcure and Sanofi India were trading at Rs 1,382 and 5,971, higher by 1.5 percent, each. Emcure Pharma shares are down 7 since the beginning of the year, while Sanofi India is up 9 percent in six months.